These companies could innovate their way to success.

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

To our immune system, a potentially lifesaving gene therapy can look a lot like a dangerous infection. That's because most ...

Global CRISPR Technology Market OverviewThe global CRISPR technology market is poised for strong expansion, projected to grow at a robust CAGR of approximately 16% over the next five years. This ...

To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

Drug development in biotechnology takes time. A lot of time. On average, it takes 10 to 15 years to take a medicine from ...

Penn Medicine shows how sustained research investment drives innovation, economic growth, and global health breakthroughs.

MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can ...

He was cast as a real-life Dr Frankenstein, a scientist whose ego had led him to tamper with human life. After more than a hundred Chinese scientists issued a statement condemning his experiment, ...